Edematous Fibrosclerotic Panniculopathy Clinical Trial
Official title:
A Phase 2b, Open-label Long-term Durability Study of CCH Following Treatment of Edematous Fibrosclerotic Panniculopathy (Cellulite)
This study will evaluate the long-term safety and duration of efficacy of CCH in the treatment of women with cellulite. This study will be a single day evaluation, approximately 48 months after the first dose of study drug was received in the EN3835-201.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03675685 -
Safety and Pharmacokinetics of a Single Dose of CCH (3.36 mg) in Subjects With EFP
|
Phase 1 | |
| Completed |
NCT02942160 -
EN3835 for the Treatment of Edematous Fibrosclerotic Panniculopathy (Commonly Known as Cellulite)
|
Phase 2 | |
| Completed |
NCT04580303 -
CCH Treatment of Cellulite in the Presence of Dermal Laxity With Comparison Between Two (2) Different Injection Techniques
|
Phase 2 | |
| Completed |
NCT03329989 -
Safety and Effectiveness of EN3835 in the Treatment of EFP in Women
|
Phase 2 | |
| Completed |
NCT03893890 -
Durability and Safety of EN3835 in the Treatment of EFP (Cellulite) in Women
|
||
| Completed |
NCT05419505 -
Study of Different Interventions to Reduce Bruising Following CCH-Aaes Treatment for Cellulite of the Buttocks
|
Phase 2 | |
| Completed |
NCT05249257 -
Durability and Safety of CCH With Two Different Injection Techniques in Cellulite With Laxity
|
||
| Completed |
NCT01518907 -
The Safety, Effectiveness, and Pharmacokinetics of AA4500 for the Treatment of Edematous Fibrosclerotic Panniculopathy (Commonly Known as Cellulite)
|
Phase 1 | |
| Completed |
NCT02724644 -
EN3835 for the Treatment of Edematous Fibrosclerotic Panniculopathy (Commonly Known as Cellulite)
|
Phase 2 | |
| Completed |
NCT03526549 -
Long-Term Study of EN3835 (CCH-aaes) in Edematous Fibrosclerotic Panniculopathy (Cellulite)
|
Phase 3 |